Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00013156 · ClinicalTrials.gov registry record · Phase 2
Cost-Effectiveness of Lung Volume Reduction Surgery
A Phase 2 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00013156: Completed Phase 2 study, sponsored by US Department of Veterans Affairs.
NCT00013156 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00013156, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Lung volume reduction surgery (LVRS) has been advanced as a therapy to significantly improve quality of life in patients with COPD, but to date no controlled studies have evaluated the impact of LVRS.
Interventions
- PROCEDURE Effectiveness of Lung Reduction Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Est. Completion | 2000-03 |
| Phase | Phase 2 |
What the finished NCT00013156 record still lists
NCT00013156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which Effectiveness of Lung Reduction Therapy is the first listed.
NCT00013156 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00013156 about?
NCT00013156 is a clinical study titled "Cost-Effectiveness of Lung Volume Reduction Surgery". Lung volume reduction surgery (LVRS) has been advanced as a therapy to significantly improve quality of life in patients with COPD, but to date no controlled studies have evaluated the impact of LVRS.
What is the current status of trial NCT00013156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00013156?
The interventions under investigation include: Effectiveness of Lung Reduction Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00013156?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00013156's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma